

Accepted Manuscript

Title: The remarkable therapeutic potential of response-based dose individualisation in drug trials and patient care

Author: Chao Chen

PII: S1359-6446(18)30092-8
DOI: <https://doi.org/10.1016/j.drudis.2018.04.005>
Reference: DRUDIS 2217



To appear in:

Received date: 28-2-2018
Revised date: 17-3-2018
Accepted date: 6-4-2018

Please cite this article as: Chen, Chao, The remarkable therapeutic potential of response-based dose individualisation in drug trials and patient care. *Drug Discovery Today* <https://doi.org/10.1016/j.drudis.2018.04.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The remarkable therapeutic potential of response-based dose individualisation in drug trials and patient care

Chao Chen

Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Uxbridge, UB11 1BT, UK

Corresponding author: Chen, C. (chao.c.chen@gsk.com).

Highlights:

- Most drugs are reportedly effective in only 25–62% of patients
- Dose-finding trials are usually designed to find the optimal dose for the patient population
- The optimal dose for the population can be suboptimal for a large proportion of the patients in the population
- Dose titration, where appropriate, can remarkably increase the response rate without compromising the overall benefit:risk ratio
- Titration addresses relevant questions for patient care: how likely is it that a patient responds to the therapy, to what extent and at what dose?

Teaser: Titration drug trials can best inform clinical practice and maximise therapeutic benefits.

The FDA reported that most drugs are effective in only 25–62% of patients. Although many drugs require dose individualisation in clinical practice, dose-finding trials usually aim to identify an optimal dose for the patient population. Such a dose would be suboptimal for many patients. Simulations show that individualised dose titration, balancing efficacy against toxicity, can remarkably increase the response rate – doubling it in some situations. Dose titration in a clinical trial can efficiently establish the realistic expectations for the drug's true utility in a trial setting that reflects clinical practice, as well as generate important knowledge to guide patient care through informative drug labels. This design answers key questions truly relevant to patient care that other designs cannot – how likely will a patient respond, to what extent and at what dose? Therefore, response-based dose titration should be considered for dose-finding trials, where appropriate, for drugs that will eventually be used this way in the clinic.

Download English Version:

<https://daneshyari.com/en/article/8409451>

Download Persian Version:

<https://daneshyari.com/article/8409451>

[Daneshyari.com](https://daneshyari.com)